Herpes simplex virus (HSV) type 1 (HSV-1) infection is widely prevalent \[[@CIT0001], [@CIT0002]\]. With its persistent shedding \[[@CIT0003], [@CIT0004]\], HSV-1 is infectious for lifetime, but mostly subclinically and asymptomatically \[[@CIT0005]\]. When symptomatic, HSV-1 can cause mild to severe disease \[[@CIT0005], [@CIT0008]\]. Although infection is often manifested as orolabial herpes \[[@CIT0005], [@CIT0008]\], the virus can cause a spectrum of diseases such as herpetic whitlow, gingivostomatitis, meningitis, encephalitis, corneal blindness, and neonatal herpes \[[@CIT0008], [@CIT0009]\].

HSV-1 clinical manifestations are determined by the virus's initial portal of entry \[[@CIT0005], [@CIT0008]\]. Although it is predominantly transmitted through oral shedding \[[@CIT0005]\], leading to oral manifestations \[[@CIT0005], [@CIT0008]\], HSV-1 can be transmitted sexually, leading to genital herpes, given the portal of entry \[[@CIT0005], [@CIT0006], [@CIT0010]\].

HSV-1 antibody prevalence (seroprevalence) seems to be very high globally, with the majority of affected persons seroconverting by the time they reach puberty \[[@CIT0002], [@CIT0011], [@CIT0012]\]. However, with continuing improvement in hygiene and living conditions, seroprevalence seems to have declined, at least in Western countries \[[@CIT0011], [@CIT0013]\]. About half of youth there reach sexual debut before being exposed (nonsexually) to HSV-1 and thus are at risk of acquiring the infection genitally \[[@CIT0005], [@CIT0021]\]. Evidence indicates a growing role for HSV-1 as a sexually transmitted infection (STI) and as a leading, if not *the* leading, cause of initial episodes of genital herpes in Western countries \[[@CIT0005], [@CIT0021]\].

Although this striking transition in HSV-1 epidemiology in the West is well documented \[[@CIT0005], [@CIT0007], [@CIT0026]\], the extent to which it is occurring elsewhere is unknown. Understanding HSV-1 epidemiology in different regions will help characterize the HSV-1 burden, oral and genital, and target the most affected populations with interventions. To this end, the World Health Organization and global partners are spearheading efforts to accelerate the development of HSV vaccines \[[@CIT0027], [@CIT0028]\]. A business case is being developed that factors public health needs, pathways of vaccine rollout, impact and cost-effectiveness, and return on investment \[[@CIT0027]\]. To inform this effort, it is critical to establish current infection levels and trends.

Our overarching goals were to assess HSV-1 seroprevalence levels and trends in Asia and the extent to which HSV-1 is the cause of genital ulcer disease (GUD) and genital herpes. We specifically aimed to (1) methodologically review and synthesize available studies on seroprevalence; (2) estimate seroprevalence in different populations and ages by pooling existing measures; (3) assess seroprevalence temporal trend, population-level associations with seroprevalence, and sources of between-study heterogeneity; (4) assess the proportion of HSV-1 viral detection in clinically diagnosed GUD; and (5) assess the proportion of HSV-1 viral detection in clinically diagnosed genital herpes. The distinction between the last 2 aims lies in the denominator---the etiology of GUD includes several indications other than HSV-1 infection (diagnosis of any GUD) \[[@CIT0029]\], and the etiology of genital herpes includes only HSV-1 and HSV type 2 (HSV-2) infections (virological diagnosis of herpes) \[[@CIT0030]\].

MATERIALS AND METHODS {#s5}
=====================

Data Sources and Search Strategy {#s6}
--------------------------------

This systematic review was informed by the Cochrane Collaboration Handbook \[[@CIT0031]\] and followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines \[[@CIT0032]\]. The PRISMA checklist is in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Available HSV-1 publications in PubMed (from 1950) and Embase (from 1974) databases were systematically reviewed until 22 April 2018. For inclusiveness, broad search criteria were used, with MeSH/Emtree terms exploded to cover all subheadings and with no language or year restrictions ([Supplementary Box 1](#sup1){ref-type="supplementary-material"}). Articles in Chinese, English, French, and Japanese were reviewed in their original language. Articles in other languages were translated. Asia region definition was informed by the World Health Organizations definitions for South-East Asia and Western Pacific regions \[[@CIT0033]\]. The list of included countries/territories is in [Supplementary Box 2](#sup1){ref-type="supplementary-material"}.

Study Selection and Inclusion/Exclusion Criteria {#s7}
------------------------------------------------

Search results were imported into Endnote (a reference manager), where duplicate publications were identified and excluded. Titles and abstracts of remaining records were screened for relevance, and full texts of relevant and potentially relevant publications were retrieved for additional screening. References of articles and reviews were also checked to identify further publications that could have been missed.

The inclusion criteria were met for any publication that reported HSV-1 seroprevalence measure(s), based on primary data using type-specific diagnostic assays such as Western blot or type-specific (glycoprotein-G-based) enzyme-linked immunosorbent assays (ELISAs). The inclusion criteria were also met for any publication that reported a proportion of HSV-1 detection by standard viral detection and subtyping methods in GUD or genital herpes---to estimate the "etiological" (or "associative") fraction for HSV-1 in these clinical conditions. Included studies had to have a sample size of ≥10, regardless of outcome measure.

Exclusion criteria included case reports, case series, reviews, editorials, letters to editors, commentaries, and qualitative studies. Measures reporting seroprevalence in \<3-month-old infants were excluded because of maternal antibodies.

For terminology, a "publication" is a document containing a relevant outcome measure, and a "study" or a "measure" indicates all details pertaining to a specific outcome measure---a single publication may contribute multiple measures, and multiple publications of the same data set are deemed a single study.

Data Extraction and Data Synthesis {#s8}
----------------------------------

Extracted variables included author(s), publication title, year(s) of data collection, publication year, country of origin, country of survey, city, study site, study design, study sampling procedure, study population and its characteristics (eg, sex and age), sample size, HSV-1 outcome measures, and diagnostic assay. Data from relevant publications were double extracted by L. K. and M. H., with input from R. O.

Extracted overall outcome measures were substituted with stratified measures, provided the sample size requirement was fulfilled for each stratum. The stratification hierarchy for seroprevalence included population type, age bracket, and age group, for epidemiological relevance and analysis. In age-bracket stratification, we aimed to assess seroprevalence in adults (≥15 years of age) versus children (\<15 years). In age-group stratification, we aimed to assess seroprevalence growth with age (\<20, 20--39, or ≥40 years); these strata were optimal given reported age-stratified data. Stratification hierarchy for GUD and genital herpes proportions included ethnicity, study site (eg, hospital or STI clinic), and genital herpes episode (first vs recurrent).

Extracted seroprevalence measures were stratified by population type into (1) healthy general populations, consisting of healthy populations such as blood donors, pregnant women, and outpatients with minor health conditions; (2) clinical populations, consisting of any population with a major clinical condition, or a condition related (potentially) to HSV-1 infection; and (3) other populations, consisting of the remaining populations not satisfying the above definitions or populations with an undetermined risk of acquiring HSV-1, such as persons with human immunodeficiency virus infection, sex workers, and men who have sex with men.

Meta-analyses {#s9}
-------------

Meta-analyses were conducted to estimate pooled mean HSV-1 seroprevalence by population type and by age bracket or group and to estimate the pooled mean proportions of HSV-1 detection in GUD and genital herpes.

Pooled means were estimated using DerSimonian-Laird random-effects models \[[@CIT0034]\], provided that ≥3 measures were available. This method accounts for sampling variation and heterogeneity in effect size (seroprevalence or GUD/genital herpes proportion) \[[@CIT0034]\]. The Freeman-Tukey double-arcsine transformation was used for variance stabilization \[[@CIT0035]\].

The Cochran *Q* statistic was calculated to assess existence of heterogeneity in effect size (*P* \< .10 indicated heterogeneity) \[[@CIT0036], [@CIT0037]\]. The *I*^2^ heterogeneity measure was estimated to assess the percentage of between-study variation in effect size that is due to actual differences in effect size rather than chance \[[@CIT0037]\]. Prediction intervals were calculated to describe the heterogeneity in meta-analyses \[[@CIT0036], [@CIT0037]\]. Meta-analyses were performed in R software, version 3.4.1 \[[@CIT0038]\] using the meta package \[[@CIT0039]\].

Meta-regression Analyses {#s10}
------------------------

Univariable and multivariable random-effects meta-regression analyses were conducted to identify predictors of HSV-1 seroprevalence (including temporal trend) and sources of between-study heterogeneity. The log-transformed proportions were regressed to estimate risk ratios.

Relevant independent variables were specified a priori: age bracket, age group, assay type (Western blot, ELISA, or other), country's income, population type, sample size (\<100 vs ≥100 subjects), sampling method (probability-based vs non--probability-based sampling), sex, year of data collection, and year of publication. Factors associated with seroprevalence at *P* ≤ .10 in univariable analysis were included in the final multivariable analysis. Factors associated with seroprevalence at *P* ≤ .05 in the final multivariable analysis were deemed statistically significant.

For the country's income variable, countries with available data were grouped according to the World Bank classification \[[@CIT0040]\]. For measures that did not include a year of data collection, missing values were imputed using the median of the values calculated by subtracting the year of data collection (when available) from the year of publication. Meta-regression analyses were conducted with Stata/SE software, version 13 \[[@CIT0041]\], using the metareg package \[[@CIT0042]\].

Quality Assessment {#s11}
------------------

For diagnostic methods, diversity, and potential issues of sensitivity or specificity \[[@CIT0043], [@CIT0044]\], we performed quality assessment with the support of an expert advisor, Rhoda Ashley-Morrow, University of Washington, Seattle. Only publications with sufficiently reliable assays were eligible for inclusion. Study quality was further assessed by conducting risk of bias (ROB) assessment (as informed by the Cochrane approach \[[@CIT0031]\]) and precision assessment.

Studies were categorized as low versus high ROB using 2 quality domains assessing the rigor of sampling method (probability based vs otherwise) and response rate (≥80% vs otherwise). A study was considered to have high (vs low) precision if the sample size was ≥100.

RESULTS {#s12}
=======

Search Results and Scope of Evidence {#s13}
------------------------------------

[Figure 1](#F1){ref-type="fig"} describes the study-selection process based on PRISMA guidelines \[[@CIT0032]\]. A total of 3517 citations were identified (988 through PubMed and 2529 through Embase). Of these, 528 were relevant or potentially relevant after removal of duplicates and screening of titles and abstracts. Eventually, 45 publications were eligible for inclusion after full-text screening. Four additional publications were identified through screening of bibliographies of publications and reviews \[[@CIT0045]\].

![Flow chart of article selection for the systematic review of herpes simplex virus type 1 (HSV-1) in Asia, as adapted from the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2009 guidelines \[[@CIT0032]\].](ciy56201){#F1}

A total of 54 overall seroprevalence measures (distinct overall measures in different populations) were extracted, and these yielded 182 stratified seroprevalence measures. Eight proportions of HSV-1 detection in GUD and 24 proportions in genital herpes were further extracted. Extracted measures originated from 13 of 26 Asian countries/territories.

Seroprevalence Overview {#s14}
-----------------------

[Table 1](#T1){ref-type="table"} summarizes the stratified seroprevalence measures. The earliest measure was published in 1986. Most measures were based on cross-sectional study design (n = 152 measures; 83.5%), and convenience sampling (n = 150; 82.4%).

###### 

Studies Reporting Herpes Simplex Virus Type 1 Seroprevalence Among Different Populations in Asia

  Authors (Year)                                                                      Year(s) of Data Collection   Country       Study Site          Study Design   Sampling Method   Population                               HSV-1 Serological Assay   Sample Size, No.   HSV-1 Seroprevalence, %
  ----------------------------------------------------------------------------------- ---------------------------- ------------- ------------------- -------------- ----------------- ---------------------------------------- ------------------------- ------------------ -------------------------
  **Healthy Children Populations (n** = **19**)                                                                                                                                                                                                                             
  Bogaerts et al (2001) \[[@CIT0049]\]                                                1996--1998                   Bangladesh    Outpatient clinic   CS             Conv              1--12-y-old children                     WB                        79                 46.0
  Chang (1986) \[[@CIT0050]\]                                                         1984--1986                   China         Hospital            CS             Conv              7--12-mo-old infants                     CFT                       31                 41.9
  Chang (1986) \[[@CIT0050]\]                                                         1984--1987                   China         Hospital            CS             Conv              13--24-mo-old children                   CFT                       31                 51.6
  Chang (1986) \[[@CIT0050]\]                                                         1984--1988                   China         Hospital            CS             Conv              24--35-mo-old children                   CFT                       30                 43.3
  Chang (1986) \[[@CIT0050]\]                                                         1984--1989                   China         Hospital            CS             Conv              3--4-y-old children                      CFT                       31                 67.7
  Chang (1986) \[[@CIT0050]\]                                                         1984--1990                   China         Hospital            CS             Conv              5--6-y-old children                      CFT                       31                 48.4
  Chang (1986) \[[@CIT0050]\]                                                         1984--1991                   China         Hospital            CS             Conv              7--8-y-old children                      CFT                       31                 71.0
  Chang (1986) \[[@CIT0050]\]                                                         1984--1992                   China         Hospital            CS             Conv              9--14-y-old children                     CFT                       31                 74.2
  Chen et al (2013) \[[@CIT0051]\]                                                    2007                         Taiwan        Community           CS             Conv              1-y-old children                         ELISA                     90                 11.1
  Chen et al (2013) \[[@CIT0051]\]                                                    2007                         Taiwan        Community           CS             Conv              2-y-old children                         ELISA                     127                14.2
  Chen et al (2013) \[[@CIT0051]\]                                                    2007                         Taiwan        Community           CS             Conv              3-y-old children                         ELISA                     92                 31.5
  Chen et al (2013) \[[@CIT0051]\]                                                    2007                         Taiwan        Community           CS             Conv              4-y-old children                         ELISA                     84                 23.8
  Chen et al (2013) \[[@CIT0051]\]                                                    2007                         Taiwan        Community           CS             Conv              5--9-y-old children                      ELISA                     111                46.8
  Chen et al (2013) \[[@CIT0051]\]                                                    2007                         Taiwan        Community           CS             Conv              10--14-y-old children                    ELISA                     92                 46.7
  Li et al (1990) \[[@CIT0052]\]                                                      1988--1989                   China         Community           CS             Conv              1--10-y-old Koreans                      PHA                       16                 38.0
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                5--9-y-old girls                         ELISA                     40                 64.9
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                10--14-y-old girls                       ELISA                     45                 78.3
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                5--9-y-old boys                          ELISA                     75                 59.8
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                10--14-y-old boys                        ELISA                     64                 78.0
  **Healthy Adult Populations (n** = **103**)                                                                                                                                                                                                                               
  Armelia et al (2012) \[[@CIT0054]\]                                                 2010--2011                   Indonesia     Hospital            CS^a^          Conv              Kidney donors                            Anti-HSV-1 IgG            23                 72.7
  Ashley et al (2004) \[[@CIT0055]\]                                                  2000--2001                   Thailand      Community           CS             Conv              ≥15-y-old women in Lampang               WB                        98                 92.9
  Ashley et al (2004) \[[@CIT0055]\]                                                  2000--2001                   Thailand      Community           CS             Conv              ≥15-y-old women in Songkla               WB                        90                 61.1
  Ashley et al (2004) \[[@CIT0055]\]                                                  2000--2001                   Vietnam       Community           CS             Conv              ≥15-y-old women in Hanoi                 WB                        99                 100.0
  Ashley et al (2004) \[[@CIT0055]\]                                                  2000--2001                   Vietnam       Community           CS             Conv              ≥15-y-old women in Ho Chi Minh           WB                        100                98.0
  Bogaerts et al (2001) \[[@CIT0049]\]                                                1996--1998                   Bangladesh    Outpatient clinic   CS             Conv              Healthy women                            ELISA                     183                97.0
  Bu et al (2015) \[[@CIT0045]\]                                                      2012--2013                   China         Hospital            CC             Conv              Healthy individuals                      ELISA                     135                78.5
  Chang (1986) \[[@CIT0050]\]                                                         1984--1986                   China         Hospital            CS             Conv              \>14-y-old adults                        CFT                       30                 93.3
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   India         Community           CS             Conv              15--20-y-old adults                      ELISA                     239^b^             85.7
  Chen et al (2013) \[[@CIT0051]\]                                                    2007                         Taiwan        Community           CS             Conv              15--19-y-old adults                      ELISA                     115                53.0
  Chen et al (2013) \[[@CIT0051]\]                                                    2007                         Taiwan        Community           CS             Conv              20--29-y-old adults                      ELISA                     123                69.9
  Chen et al (2013) \[[@CIT0051]\]                                                    2007                         Taiwan        Community           CS             Conv              30--39-y-old adults                      ELISA                     129                84.5
  Chen et al (2013) \[[@CIT0051]\]                                                    2007                         Taiwan        Community           CS             Conv              40--49-y-old adults                      ELISA                     100                94.0
  Chen et al (2013) \[[@CIT0051]\]                                                    2007                         Taiwan        Community           CS             Conv              50--59-y-old adults                      ELISA                     91                 98.9
  Chen et al (2013) \[[@CIT0051]\]                                                    2007                         Taiwan        Community           CS             Conv              60--69-y-old adult                       ELISA                     122                100
  Chen et al (2013) \[[@CIT0051]\]                                                    2007                         Taiwan        Community           CS             Conv              \>70-y-old adults                        ELISA                     96                 100
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   India         Community           CS             Conv              20--30-y-old adults                      ELISA                     239^b^             79.9
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   India         Community           CS             Conv              30--35-y-old adults                      ELISA                     239^b^             80.0
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   India         Community           CS             Conv              25--40-y-old adults                      ELISA                     239^b^             84.8
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   India         Community           CS             Conv              40--45-y-old adults                      ELISA                     239^b^             86.2
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   India         Community           CS             Conv              \>45-y-old adults                        ELISA                     239^b^             92.5
  Doi et al (2009) \[[@CIT0057]\]                                                     2002                         Japan         Community           CS^a^          RS                18--29-y-old women                       ELISA                     83                 45.8
  Doi et al (2009) \[[@CIT0057]\]                                                     2002                         Japan         Community           CS^a^          RS                30--39-y-old women                       ELISA                     184                50.5
  Doi et al (2009) \[[@CIT0057]\]                                                     2002                         Japan         Community           CS^a^          RS                40--49-y-old women                       ELISA                     198                66.7
  Doi et al (2009) \[[@CIT0057]\]                                                     2002                         Japan         Community           CS^a^          RS                50--59-y-old women                       ELISA                     200                79.0
  Doi et al (2009) \[[@CIT0057]\]                                                     2002                         Japan         Community           CS^a^          RS                18--29-y-old men                         ELISA                     45                 44.4
  Doi et al (2009) \[[@CIT0057]\]                                                     2002                         Japan         Community           CS^a^          RS                30--39-y-old men                         ELISA                     129                44.2
  Doi et al (2009) \[[@CIT0057]\]                                                     2002                         Japan         Community           CS^a^          RS                40--49-y-old men                         ELISA                     198                49.0
  Doi et al (2009) \[[@CIT0057]\]                                                     2002                         Japan         Community           CS^a^          RS                50--59-y-old men                         ELISA                     198                71.7
  Hashido et al (1998) \[[@CIT0058]\]                                                 NA                           Japan         Community           CS             Conv              \<30-y-old men blood donors              EIA                       12                 33.0
  Hashido et al (1998) \[[@CIT0058]\]                                                 NA                           Japan         Community           CS             Conv              30--50-y-old men blood donors            EIA                       17                 70.0
  Hashido et al (1998) \[[@CIT0058]\]                                                 NA                           Japan         Community           CS             Conv              \>50-y-old men blood donors              EIA                       12                 92.0
  Hashido et al (1998) \[[@CIT0058]\]                                                 NA                           Japan         Community           CS             Conv              20--39-y-old healthy women               EIA                       20                 65.0
  Hashido et al (1998) \[[@CIT0058]\]                                                 NA                           Japan         Community           CS             Conv              40--99-y-old healthy women               EIA                       28                 89.0
  Hashido et al (1998) \[[@CIT0058]\]                                                 NA                           Japan         Community           CS             Conv              \>50-y-old healthy women                 EIA                       27                 92.5
  Hashido et al (1998) \[[@CIT0058]\]                                                 NA                           Japan         Community           CS             Conv              Pregnant women from Tokyo                EIA                       58                 47.0
  Hashido et al (1998) \[[@CIT0058]\]                                                 NA                           Japan         Community           CS             Conv              Pregnant women from Kagoshima            EIA                       100                61.0
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              20--29-y-old men in 1973                 ELISA                     31                 64.5
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              30--39-y-old men in 1973                 ELISA                     25                 76.0
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              40--49-y-old men in 1973                 ELISA                     15                 86.7
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              20--29-y-old men in 1983                 ELISA                     24                 37.5
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              30--39-y-old men in 1983                 ELISA                     30                 76.7
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              40--49-y-old men in 1983                 ELISA                     33                 90.9
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              20--29-y-old men in 1993                 ELISA                     30                 33.3
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              30--39-y-old men in 1993                 ELISA                     30                 56.7
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              40--49-y-old men in 1993                 ELISA                     45                 75.6
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              20--29-y-old women in 1973               ELISA                     32                 59.4
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              30--39-y-old women in 1973               ELISA                     33                 84.8
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              40--49-y-old women in 1973               ELISA                     23                 100.0
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              20--29-y-old women in 1983               ELISA                     35                 51.4
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              30--39-y-old women in 1983               ELISA                     36                 77.8
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              40--49-y-old women in 1983               ELISA                     34                 97.1
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              20--29-y-old women in 1993               ELISA                     63                 31.7
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              30--39-y-old women in 1993               ELISA                     54                 69.1
  Hashido et al (1999) \[[@CIT0059]\]                                                 1973--1993                   Japan         Community           CS             Conv              40--49-y-old women in 1993               ELISA                     41                 80.5
  Kaur et al (1999) \[[@CIT0060]\]                                                    NA                           India         Outpatient clinic   CS             Conv              16--20-y-old pregnant women              EIA                       24                 50.0
  Kaur et al (1999) \[[@CIT0060]\]                                                    NA                           India         Outpatient clinic   CS             Conv              21--25-y-old pregnant women              EIA                       36                 44.4
  Kaur et al (1999) \[[@CIT0060]\]                                                    NA                           India         Outpatient clinic   CS             Conv              26--30-y-old pregnant women              EIA                       34                 55.8
  Kaur et al (1999) \[[@CIT0060]\]                                                    NA                           India         Outpatient clinic   CS             Conv              31--35-y-old pregnant women              EIA                       14                 14.1
  Kaur et al (1999) \[[@CIT0060]\]                                                    NA                           India         Outpatient clinic   CS             Conv              \>36-y-old pregnant women                EIA                       12                 83.3
  Kaur et al (2005) \[[@CIT0061]\]                                                    NA                           India         Outpatient clinic   CS             Conv              16--20-y-old women                       ELISA                     12                 50.0
  Kaur et al (2005) \[[@CIT0061]\]                                                    NA                           India         Outpatient clinic   CS             Conv              21--25-y-old women                       ELISA                     17                 47.1
  Kaur et al (2005) \[[@CIT0061]\]                                                    NA                           India         Outpatient clinic   CS             Conv              26--30-y-old women                       ELISA                     18                 50.0
  Kaur et al (2005) \[[@CIT0061]\]                                                    NA                           India         Outpatient clinic   CS             Conv              31--40-y-old women                       ELISA                     13                 46.1
  Kaur et al (2005) \[[@CIT0061]\]                                                    NA                           India         Outpatient clinic   CS             Conv              16--20-y-old men                         ELISA                     13                 46.1
  Kaur et al (2005) \[[@CIT0061]\]                                                    NA                           India         Outpatient clinic   CS             Conv              21--25-y-old men                         ELISA                     20                 25.0
  Kaur et al (2005) \[[@CIT0061]\]                                                    NA                           India         Outpatient clinic   CS             Conv              26--30-y-old men                         ELISA                     14                 71.4
  Kaur et al (2005) \[[@CIT0061]\]                                                    NA                           India         Outpatient clinic   CS             Conv              31--40-y-old men                         ELISA                     13                 46.1
  Li et al (1990) \[[@CIT0052]\]                                                      1988--1989                   China         Community           CS             Conv              \>21-y-old Hans Chinese                  PHA                       78                 99.0
  Li et al (1990) \[[@CIT0052]\]                                                      1988--1989                   China         Community           CS             Conv              \>21-y-old Koreans                       PHA                       34                 97.0
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                15--19-y-old women                       ELISA                     78                 87.5
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                20--24-y-old women                       ELISA                     101                86.1
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                25--29-y-old women                       ELISA                     135                93.3
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                30--34-y-old women                       ELISA                     152                96.7
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                35--39-y-old women                       ELISA                     154                95.5
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                40--44-y-old women                       ELISA                     129                98.4
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                45--49-y-old women                       ELISA                     97                 98.0
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                50--54-y-old women                       ELISA                     101                98.1
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                55--60-y-old women                       ELISA                     44                 97.8
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                15--19-y-old men                         ELISA                     89                 76.5
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                20--24-y-old men                         ELISA                     93                 81.9
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                25--29-y-old men                         ELISA                     112                86.5
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                30--34-y-old men                         ELISA                     137                90.4
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                35--39-y-old men                         ELISA                     144                93.7
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                40--44-y-old men                         ELISA                     118                97.4
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                45--49-y-old men                         ELISA                     89                 96.7
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                50--54-y-old men                         ELISA                     82                 98.7
  Lin et al (2011) \[[@CIT0053]\]                                                     2006                         China         Community           CS             RS                55--60-y-old men                         ELISA                     62                 98.4
  Nasrallah GK, Dargham SR, Harfouche M, and Abu-Raddad LJ (2018, unpublished data)   2013--2016                   India         Community           CS             Conv              \<24-y-old Indian men                    ELISA                     40                 40.0
  Nasrallah GK, Dargham SR, Harfouche M, and Abu-Raddad LJ (2018, unpublished data)   2013--2016                   India         Community           CS             Conv              25--29-y-old Indian men                  ELISA                     49                 34.0
  Nasrallah GK, Dargham SR, Harfouche M, and Abu-Raddad LJ (2018, unpublished data)   2013--2016                   India         Community           CS             Conv              30--34-y-old Indian men                  ELISA                     50                 60.0
  Nasrallah GK, Dargham SR, Harfouche M, and Abu-Raddad LJ (2018, unpublished data)   2013--2016                   India         Community           CS             Conv              35--39-y-old Indian men                  ELISA                     50                 36.0
  Nasrallah GK, Dargham SR, Harfouche M, and Abu-Raddad LJ (2018, unpublished data)   2013--2016                   India         Community           CS             Conv              40--44-y-old Indian men                  ELISA                     50                 48.0
  Nasrallah GK, Dargham SR, Harfouche M, and Abu-Raddad LJ (2018, unpublished data)   2013--2016                   India         Community           CS             Conv              45--49-y-old Indian men                  ELISA                     50                 58.0
  Nasrallah GK, Dargham SR, Harfouche M, and Abu-Raddad LJ (2018, unpublished data)   2013--2016                   India         Community           CS             Conv              \>50-y-old Indian men                    ELISA                     35                 62.0
  Nasrallah GK, Dargham SR, Harfouche M, and Abu-Raddad LJ (2018, unpublished data)   2013--2016                   Philippines   Community           CS             Conv              \<34-y-old Filipino men                  ELISA                     52                 84.6
  Nasrallah GK, Dargham SR, Harfouche M, and Abu-Raddad LJ (2018, unpublished data)   2013--2016                   Philippines   Community           CS             Conv              35--44-y-old Filipino men                ELISA                     40                 82.5
  Nasrallah GK, Dargham SR, Harfouche M, and Abu-Raddad LJ (2018, unpublished data)   2013--2016                   Philippines   Community           CS             Conv              \>45-y-old Filipino men                  ELISA                     28                 85.7
  Patnaik et al (2007) \[[@CIT0062]\]                                                 1985--2007                   Thailand      Hospital            CC             Conv              Healthy women                            WB                        78                 51.3
  Schmid et al (1999) \[[@CIT0063]\]                                                  1991--1993                   Thailand      Hospital            CS             Conv              \>21-y-old army men                      WB                        1158               77.9
  Shivaswamy et al (2005) \[[@CIT0064]\]                                              2001--2003                   India         Outpatient clinic   CC             Conv              Healthy individuals                      ELISA                     135                91.8
  Yue (1990) \[[@CIT0065]\]                                                           1987--1989                   China         Outpatient clinic   CS             Conv              Pregnant women                           ELISA                     295                82.0
  Zegans et al (1999) \[[@CIT0066]\]                                                  1997                         India         Hospital            CC             Conv              Controls for a study of Mooren ulcer     ELISA                     44                 64.0
  **Healthy Mixed-Age Populations (n** = **4**)                                                                                                                                                                                                                             
  Li et al (1990) \[[@CIT0052]\]                                                      1988--1989                   China         Community           CS             Conv              11--20-y-old Hans Chinese                PHA                       17                 94.1
  Li et al (1990) \[[@CIT0052]\]                                                      1988--1989                   China         Community           CS             Conv              11--20-y-old Koreans                     PHA                       13                 85.0
  Shen et al (2015) \[[@CIT0067]\]                                                    2007                         Taiwan        Community           CS             RS                Healthy women                            ELISA                     830                64.5
  Shen et al (2015) \[[@CIT0067]\]                                                    2007                         Taiwan        Community           CS             RS                Healthy men                              ELISA                     581                52.0
  **Clinical Children Populations (n** = **7**)                                                                                                                                                                                                                             
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   India         Hospital            CS             Conv              1--5-y-old children                      ELISA                     90^b^              40.2
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   India         Hospital            CS             Conv              5--10-y-old children                     ELISA                     90^b^              68.4
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   India         Hospital            CS             Conv              10--15-y-old children                    ELISA                     90^b^              75.9
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   Sri Lanka     Hospital            CS             Conv              1--5-y-old children                      ELISA                     144^b^             40.5
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   Sri Lanka     Hospital            CS             Conv              5--10-y-old children                     ELISA                     144^b^             53.1
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   Sri Lanka     Hospital            CS             Conv              10--15-y-old children                    ELISA                     144^b^             74.0
  Shymala et al (2008) \[[@CIT0068]\]                                                 2005--2006                   India         Outpatient clinic   CS             Conv              Infants with congenital cataract         ELISA                     18                 16.7
  **Clinical Adult Populations (n** = **23**)                                                                                                                                                                                                                               
  Armelia et al (2012) \[[@CIT0054]\]                                                 2010--2011                   Indonesia     Hospital            CS^a^          Conv              Pre--kidney transplant patients          Anti-HSV-1 IgG            23                 68.2
  Bu et al (2015) \[[@CIT0045]\]                                                      2012--2013                   China         Hospital            CC             Conv              Patients with Alzheimer disease          ELISA                     128                85.2
  Hashido et al (1998) \[[@CIT0058]\]                                                 NA                           Japan         Community           CS             Conv              \<39-y-old patients with STD             EIA                       10                 60.0
  Hashido et al (1998) \[[@CIT0058]\]                                                 NA                           Japan         Community           CS             Conv              \>40-y-old patients with STD             EIA                       16                 81.2
  Hashido et al (1998) \[[@CIT0058]\]                                                 NA                           Japan         Community           CS             Conv              Pregnant Tokyo women with HTLV-1         EIA                       32                 56.0
  Hashido et al (1998) \[[@CIT0058]\]                                                 NA                           Japan         Community           CS             Conv              Pregnant Kagoshima women with HTLV-1     EIA                       100                83.0
  Kaur et al (2006) \[[@CIT0069]\]                                                    NA                           India         Outpatient clinic   CS             Conv              Women attending an STD clinic            ELISA                     52                 82.7
  Kaur et al (2006) \[[@CIT0069]\]                                                    NA                           India         Outpatient clinic   CS             Conv              Women attending an STD clinic            ELISA                     76                 73.7
  Patwardhan and Bhalla (2016) \[[@CIT0070]\]                                         NA                           India         Hospital            CS             Conv              Patients with first genital herpes       ELISA                     21                 42.8
  Patwardhan and Bhalla (2016) \[[@CIT0070]\]                                         NA                           India         Hospital            CS             Conv              Patients with recurrent genital herpes   ELISA                     23                 65.2
  Shivaswamy et al (2005) \[[@CIT0064]\]                                              2001--2003                   India         Outpatient clinic   CC             Conv              \<40-y-old patients in an STI clinic     ELISA                     111                90.1
  Shivaswamy et al (2005) \[[@CIT0064]\]                                              2001--2003                   India         Outpatient clinic   CC             Conv              ≥40-y-old patients in an STI clinic      ELISA                     24                 95.8
  Sun et al (2005) \[[@CIT0048]\]                                                     NA                           China         Hospital            CS             Conv              Diabetic inpatients                      ELISA                     206                46.1
  Sun et al (2005) \[[@CIT0048]\]                                                     NA                           China         Hospital            CS             Conv              Nondiabetic inpatients                   ELISA                     1360               36.3
  Theng et al (2006) \[[@CIT0071]\]                                                   2003--2004                   Singapore     Outpatient clinic   CS             Conv              \<29-y-old men                           ELISA                     72                 47.2
  Theng et al (2006) \[[@CIT0071]\]                                                   2003--2004                   Singapore     Outpatient clinic   CS             Conv              30--39-y-old men                         ELISA                     50                 52.0
  Theng et al (2006) \[[@CIT0071]\]                                                   2003--2004                   Singapore     Outpatient clinic   CS             Conv              40--49-y-old men                         ELISA                     41                 58.8
  Theng et al (2006) \[[@CIT0071]\]                                                   2003--2004                   Singapore     Outpatient clinic   CS             Conv              \>50-y-old men                           ELISA                     37                 78.4
  Theng et al (2006) \[[@CIT0071]\]                                                   2003--2004                   Singapore     Outpatient clinic   CS             Conv              \<20-y-old female patients               ELISA                     28                 32.1
  Theng et al (2006) \[[@CIT0071]\]                                                   2003--2004                   Singapore     Outpatient clinic   CS             Conv              20--29-y-old women                       ELISA                     98                 49.0
  Theng et al (2006) \[[@CIT0071]\]                                                   2003--2004                   Singapore     Outpatient clinic   CS             Conv              30--39-y-old women                       ELISA                     40                 67.5
  Theng et al (2006) \[[@CIT0071]\]                                                   2003--2004                   Singapore     Outpatient clinic   CS             Conv              \>40-y-old women                         ELISA                     32                 78.2
  Zegans et al (1999) \[[@CIT0066]\]                                                  1999                         India         Hospital            CS             Conv              Patients with Mooren ulcers              ELISA                     21                 86.0
  **Clinical Mixed-Age Population (n** = **1**)                                                                                                                                                                                                                             
  Lee and Lee (2015) \[[@CIT0072]\]                                                   NA                           South Korea   Community           CS^a^          Conv              \>11-y-old patients                      Multiplex immunoassay     2317               73.8
  **Other Populations (n** = **25**)                                                                                                                                                                                                                                        
  Chu et al (2006) \[[@CIT0073]\]                                                     NA                           Thailand      Hospital            CS             Conv              HIV-infected men                         ELISA                     66                 53.0
  Chu et al (2006) \[[@CIT0073]\]                                                     NA                           Thailand      Hospital            CS             Conv              HIV-infected women                       ELISA                     70                 73.0
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   Sri Lanka     Outpatient clinic   CS             Conv              15--20-y-old healthy/clinical patients   ELISA                     622^b^             74.3
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   Sri Lanka     Outpatient clinic   CS             Conv              20--30-y-old healthy/clinical patients   ELISA                     622^b^             79.2
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   Sri Lanka     Outpatient clinic   CS             Conv              30--35-y-old health/clinical patients    ELISA                     622^b^             74.6
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   Sri Lanka     Outpatient clinic   CS             Conv              25--40-y-old healthy/clinical patients   ELISA                     622^b^             74.5
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   Sri Lanka     Outpatient clinic   CS             Conv              40--45-y-old healthy/clinical patients   ELISA                     622^b^             77.1
  Cowan et al (2003) \[[@CIT0056]\]                                                   1998--2000                   Sri Lanka     Outpatient clinic   CS             Conv              \>45-y-old healthy/clinical patients     ELISA                     622^b^             82.0
  Hashido et al (1998) \[[@CIT0058]\]                                                 NA                           Japan         Community           CS             Conv              Female sex workers                       EIA                       70                 75.7
  Hashido et al (1998) \[[@CIT0058]\]                                                 NA                           Japan         Community           CS             Conv              \<39-y-old MSM                           EIA                       15                 53.3
  Hashido et al (1998) \[[@CIT0058]\]                                                 NA                           Japan         Community           CS             Conv              \>40-y-old MSM                           EIA                       19                 97.4
  Lin et al (2011) \[[@CIT0053]\]                                                     NA                           China         Community           CS             Conv              18--29-y-old HIV-infected patients       ELISA                     191                94.3
  Lin et al (2011) \[[@CIT0053]\]                                                     NA                           China         Community           CS             Conv              30--39-y-old HIV-infected patients       ELISA                     503                92.6
  Lin et al (2011) \[[@CIT0053]\]                                                     NA                           China         Community           CS             Conv              40--49-y-old HIV-infected patients       ELISA                     290                89.7
  Lin et al (2011) \[[@CIT0053]\]                                                     NA                           China         Community           CS             Conv              50--59-y-old HIV-infected patients       ELISA                     96                 85.4
  Lin et al (2011) \[[@CIT0053]\]                                                     NA                           China         Community           CS             Conv              60--94-y-old HIV-infected patients       ELISA                     30                 93.3
  Limpakarnjanara et al (1999) \[[@CIT0074]\]                                         1994                         Thailand      Community           CS             Conv              \>16-y-old female sex workers            WB                        500                91.0
  Neal et al (2011) \[[@CIT0075]\]                                                    NA                           China         Community           CS             Conv              Sex workers                              WB                        273                91.9
  Qutub and Akhter (2003) \[[@CIT0076]\]                                              NA                           Bangladesh    Community           CS^a^          Conv              Female sex workers                       WB                        463                92.7
  Theng et al (2006) \[[@CIT0077]\]                                                   2003--2004                   Singapore     Outpatient clinic   CS             Conv              20--29-y-old sex workers                 ELISA                     146                80.1
  Theng et al (2006) \[[@CIT0077]\]                                                   2003--2004                   Singapore     Outpatient clinic   CS             Conv              30--39-y-old sex workers                 ELISA                     56                 67.9
  Theng et al (2006) \[[@CIT0077]\]                                                   2003--2004                   Singapore     Outpatient clinic   CS             Conv              40--49-y-old sex workers                 ELISA                     60                 68.3
  Theng et al (2006) \[[@CIT0077]\]                                                   2003--2004                   Singapore     Outpatient clinic   CS             Conv              \>50-y-old sex workers                   ELISA                     38                 89.5
  Van Griensven et al (2013) \[[@CIT0078]\]                                           2006--2010                   Thailand      Community           CS             Conv              \>18-y-old MSM                           ELISA                     1740               56.5
  Yap et al (2017) \[[@CIT0079]\]                                                     NA                           Malaysia      Hospital            CS             Conv              HIV-infected patients                    ELISA                     232                70.7

Abbreviations: CC, case-control; CFT, complement fixation test; Conv, convenience; CS, cross-sectional; EIA, enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; HIV, human immunodeficiency virus; HSV-1, herpes simplex virus type 1; HTLV-1, human T-lymphotropic virus 1; MSM, men who have sex with men; NA, not available; PHA, passive hemagglutination assay; RS, random sampling; STD, sexually transmitted disease; STI, sexually transmitted infection; WB, Western blot.

^a^The actual study design was cohort, but the extracted seroprevalence measure was for the baseline measurement.

^b^The study included overall sample size but no sample sizes for individual strata. Each stratum sample size was assumed to be equal to the overall sample size divided by the number of strata in the study.

Extracted stratified seroprevalence measures varied across and within populations, with a range of 11.1%--100% and a median of 74.1% ([Table 2](#T2){ref-type="table"}). The range and median for seroprevalence were 11.1%--78.3% and 46.8%, respectively, in populations of healthy children (n = 19), 16.7%--75.9% and 53.1% in clinical populations of children (n = 7), 14.1%--100% and 78.5% in healthy adult populations (n = 103), and 32.1%--95.8% and 67.5% in clinical adult populations (n = 23). [Table 2](#T2){ref-type="table"} also includes the ranges and medians for further populations.

###### 

Pooled Mean Estimates for Herpes Simplex Virus Type 1 Seroprevalence Among Different Populations in Asia

  Population Type                        Outcome Measures, Total No.   Samples, Total No.   HSV-1 Seroprevalence   Pooled Mean HSV-1 Seroprevalence, Mean (95% CI)   Heterogeneity Measures^a^                                               
  -------------------------------------- ----------------------------- -------------------- ---------------------- ------------------------------------------------- --------------------------- ------------------- ----------------------- ----------------
  Healthy general populations                                                                                                                                                                                                                
   Children                              19                            1131                 11.1--78.3             46.8                                              48.5 (37.8--59.3)           228.6 (*\<*.001)    92.1 (89.1--94.3)       7.1--91.2
   Adults                                103                           9514                 14.1--100              78.5                                              77.4 (73.4--81.1)           1841.6 (*\<*.001)   94.5 (93.7--95.1)       34.9--100
   Mixed ages                            4                             1441                 52.0--94.1             74.8                                              68.9 (56.3--80.3)           36.5 (*\<*.001)     91.8 (82.2--96.2)       16.6--100
  All healthy general populations        126                           12086                11.1--100              73.4                                              73.1 (68.9--77.1)           2955.4 (*\<*.001)   95.8 (95.3--96.2)       25.3--100
  Clinical populations                                                                                                                                                                                                                       
   Children                              7                             720                  16.7--75.9             53.1                                              54.2 (40.5--67.6)           78.4 (*\<*.001)     92.3 (86.8--95.6)       11.0--93.9
   Adults                                23                            2601                 32.1--95.8             67.5                                              67.1 (56.7--76.8)           456.4 (*\<*.001)    95.2 (93.8--96.3)       17.3--100
   Mixed ages                            1^b^                          2317                 \-                     \-                                                73.8 (71.9--75.6)           \-^b^               \-^b^                   \-^b^
   All clinical populations              31                            5638                 16.7--95.8             67.5                                              64.3 (56.3--71.9)           809.2 (*\<*.001)    96.3 (95.5--97.0)       21.1--97.0
  Other populations                                                                                                                                                                                                                          
   HIV-infected patients                 8                             1476                 53.0--94.3             87.6                                              83.3 (74.0--91.0)           119.4 (*\<*.001)    94.1 (90.6--96.3)       45.7--100
   MSM                                   3                             1774                 53.3--97.4             56.5                                              69.7 (42.9--91.7)           15.5 (\<.001)       87.1 (63.2--95.5)       0.0--100
   Sex workers                           8                             1606                 67.9--92.7             84.9                                              84.1 (77.6--89.7)           63.2 (*\<*.001)     88.9 (80.5--93.7)       59.3--98.6
   Healthy/ clinical adult populations   6                             3732                 74.3--82.0             75.9                                              77.0 (74.4--79.5)           18.0 (.003)         72.3 (36.0--88.0)       68.1--84.8
  Age groups                                                                                                                                                                                                                                 
   \<20 y                                37                            3101                 11.1--94.1             51.6                                              55.5 (47.5--63.4)           654.8 (*\<*.001)    94.5 (93.3--95.5)       11.7--94.6
   20--39 y                              48                            5601                 14.1--96.7             67.7                                              67.9 (62.4--73.3)           784.3 (*\<*.001)    94.0 (92.8--95.0)       23.0--96.0
   ≥40 y                                 44                            4966                 48.0--100              89.3                                              87.5 (83.4--91.1)           633.6 (*\<*.001)    93.2 (91.7--94.4)       55.2--100
   All children                          26                            1851                 11.1--78.3             47.6                                              50.0 (41.3--58.7)           343.6 (*\<*.001)    92.7 (90.5--94.4)       10.2--89.8
   All adults                            151                           20705                14.1--100              77.8                                              76.5 (73.3--79.6)           3951.1 (*\<*.001)   96.2 (95.8--96.5)       34.2--100
   All mixed-age groups                  5                             3758                 52.0--94.1             73.8                                              70.6 (59.4--80.8)           112.8 (*\<*.001)    96.5 (94.0--97.9)       29.6--98.3
  **All studies/ strata**                **182**                       **26314**            **11.1--100**          **74.1**                                          **72.9 (69.8--75.9**)       **5038.0 (.001**)   **96.4 (96.1--96.7**)   **30.3--99.4**

Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HSV-1, herpes simplex virus type 1; MSM, men who have sex with men.

^a^The Cochran *Q* statistic is a measure assessing the existence of heterogeneity in effect size; *I*^2^, a measure that assesses the magnitude of between-study variation due to actual differences in effect size across studies rather than chance; and prediction interval, a measure that estimates the distribution (95% interval) of true effect sizes around the estimated mean.

^b^No meta-analysis was done owing to the small number of studies (n \< 3).

Pooled Seroprevalence Estimates {#s15}
-------------------------------

[Table 2](#T2){ref-type="table"} shows the results of the seroprevalence meta-analyses. Among children, the pooled mean seroprevalence was 48.5% (n = 19; 95% confidence interval \[CI\], 37.8%--59.3%) for those who were healthy and 54.2% (n = 7; 40.5%--67.6%) for those with clinical conditions. Among adults, the pooled mean was 77.4% (n = 103; 95% CI, 73.4%--81.1%) for healthy adults and 67.1% (n = 23; 56.7%--76.8%) for those with clinical conditions. [Table 2](#T2){ref-type="table"} includes pooled results for further populations. By age group, the pooled mean was lowest, at 55.5% (n = 37; 95% CI, 47.5%--63.4%), in individuals aged \<20 years, followed by 67.9% (n = 48; 62.4%--73.3%) in those aged 20--39 and 87.5% (n = 44; 83%.4--91.1%) in those aged ≥40 years.

Country-specific meta-analyses were conducted for countries with ≥5 measures for healthy children or adults. For China, the pooled means were 61.3% (n = 12; 95% CI, 53.1%--69.2%) in children and 93.1% (n = 23; 90.0%--95.6%) in adults. For India and Japan, the pooled means were 66.8% (n = 21; 95% CI, 58.6%--74.6%) and 68.1% (n = 34; 61.5%--74.6%), respectively, in healthy adults.

There was strong evidence for heterogeneity in seroprevalence in all meta-analyses (*P* \< .003; [Table 2](#T2){ref-type="table"}). Most variation was due to true variation in seroprevalence rather than sampling variation (*I*^2^ \> 50%). The prediction intervals affirmed substantial variation in seroprevalence. Forest plots are shown in [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}.

Predictors of Seroprevalence and Sources of Between-study Heterogeneity {#s16}
-----------------------------------------------------------------------

[Table 3](#T3){ref-type="table"} shows the results of the regression analyses. In univariable analyses, age bracket, age group, assay type, country's income, population type, and sampling method had *P* values of \<.10 and were included in the final multivariable analyses. Age group best explained the seroprevalence variation (adjusted *R*^*2*^ = 21.1%).

###### 

Univariable and Multivariable Meta-regression Analyses of Herpes Simplex Virus Type 1 Seroprevalence Among Different Populations in Asia

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                       Outcome Measures,\   Samples,\   Univariable Analysis   Multivariable Analysis                                                     
                                 Total No.            Total No.                                                                                                     
  ------------------------------ -------------------- ----------- ---------------------- ------------------------ ------ ---------------- -------- ---------------- --------
  Age bracket                                                                                                                                                       

   Children                      26                   1851        1.0                    ...                             1.0              ...      ...              ...

   Adults                        151                  20705       1.5 (1.3--1.7)         \<.001                          1.5 (1.3--1.7)   \<.001   ...              ...

   Mixed ages                    5                    3758        1.4 (1.1--1.9)         .01                      18.6   1.5 (1.1--2.0)   .006     ...              ...

  Age group                                                                                                                                                         

   \<20 y                        37                   3101        1.0                    ...                             ...              ...      1.0              ...

   20--39 y                      48                   5601        1.2 (1.0--1.4)         .008                            ...              ...      1.3 (1.0--1.5)   \<.001

   ≥40 y                         44                   4966        1.5 (1.3--1.8)         \<.001                          ...              ...      1.6 (1.4--1.9)   \<.001

   Mixed                         53                   12646       1.3 (1.1--1.5)         \<.001                   21.1   ...              ...      1.3 (1.1--1.5)   \<.001

  Assay type                                                                                                                                                        

   Western blot                  9                    2859        1.0                    ...                             1.0              ...      1.0              ...

   ELISA                         137                  20032       0.8 (.6--1.0)          .09                             0.9 (.8--1.1)    .63      0.9 (.7--1.0)    .28

   Others                        36                   3423        0.8 (.6--1.0)          .13                      0.5    1.0 (.8--1.2)    .98      1.0 (.8--1.2)    .72

  Country's income                                                                                                                                                  

   LMIC                          58                   8047        1.0                    ...                             1.0              ...      1.0              ...

   UMIC                          55                   10084       1.2 (1.0--1.3)         .02                             1.1 (1.0--1.3)   .01      1.1 (1.0--1.3)   .03

   HIC                           69                   8183        0.9 (.8--1.1)          .39                      7.1    0.9 (.8--1.2)    .13      0.9 (.8--.9)     .01

  Population type                                                                                                                                                   

   Healthy general populations   126                  12086       1.0                    ...                             1.0              ...      1.0              ...

   Clinical populations          31                   5638        0.9 (.8--1.0)          .17                             1.0 (.8--1.1)    .74      1.0 (.9--1.1)    .87

   Other populations             25                   8590        1.1 (1.0--1.3)         .07                      0.2    1.1 (.9--1.2)    .53      1.0 (.9--1.2)    .52

  Sample size^c^                                                                                                                                                    

   \<100                         22                   905         1.0                    ...                             ...              ...      ...              ...

   ≥100                          160                  25409       0.9 (.8--1.1)          .65                      0.0    ...              ...      ...              ...

  Sampling method                                                                                                                                                   

   Probability based             33                   7104        1.0                    ...                             1.0              ...      1.0              ...

   Non--probability based        149                  19210       0.9 (.8--1.0)          .04                      1.4    1.0 (.9--1.2)    .67      1.0 (.8--1.1)    .93

  Sex                                                                                                                                                               

   Female                        56                   5665        1.0                    ...                             ...              ...      ...              ...

   Male                          55                   6422        0.9 (.8--1.1)          .29                             ...              ...      ...              ...

   Mixed                         71                   14227       0.9 (.8--1.1)          .46                      1.4    ...              ...      ...              ...

  Year of data collection        182                  26314       1.0 (1.0--1.0)         .84                      0.0    ...              ...      ...              ...

  Year of publication            182                  26314       1.0 (1.0--1.0)         .58                      0.0    ...              ...      ...              ...
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ARR, adjusted risk ratio; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; HIC, high-income country; LMIC, lower-middle-income country; RR, risk ratio; UMIC, upper-middle-income country.

^a^The variance explained by the final multivariable model 1 (adjusted *R*^*2*^) was 26.0%

^b^The variance explained by the final multivariable model 2 (adjusted *R*^*2*^) was 33.9%

^c^Sample size denotes the sample size for each study population found in the original publication.

Sample size and sex were not statistically significant. Year of data collection and year of publication were also not statistically significant; strikingly, both risk ratios were 1.0 (95% CI, 1.0--1.0) supporting a flat seroprevalence over time.

Two final multivariable analyses were conducted, instead of one, because of collinearity between age bracket and age group. The model including age bracket, assay type, country's income, population type, and sampling method explained 26.0% of seroprevalence variation. Seroprevalence in adults was 1.5-fold (95% CI, 1.3--1.7-fold) higher than in children. Seroprevalence in upper-middle-income countries was 1.1-fold (95% CI, 1.0--1.3-fold) higher than in lower-middle-income countries. No association with assay type, population type, and sampling method was found.

The model including age group instead of age bracket explained 33.9% of seroprevalence variation and yielded similar results. Seroprevalence in individuals aged 20--39 years was 1.3-fold (95% CI, 1.0--1.5-fold) higher than in individuals \<20, and for those aged ≥40 years, it was 1.6-fold (1.4--1.9-fold) higher.

HSV-1 Detection in GUD and Genital Herpes {#s17}
-----------------------------------------

[Table 4](#T4){ref-type="table"} summarizes the studies reporting proportion of HSV-1 detection in GUD (n = 8) and genital herpes (n = 24). [Table 5](#T5){ref-type="table"} shows the results of meta-analyses, with strong evidence for heterogeneity. Forest plots are shown in [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}.

###### 

Studies From Asia Reporting Proportion of Herpes Simplex Virus Type 1 (HSV-1) Viral Detection in Clinically Diagnosed Genital Ulcer Disease, or Proportion of HSV-1 Viral Detection in Clinically Diagnosed Genital Herpes

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors (Year)                                                            Year(s) of Data Collection   Country     Study Site          Study Design   Sampling\   HSV-1 Biological Assay   Population                                      Sample Size, No.   Proportion of HSV-1 Detection, %
                                                                                                                                                        Method                                                                                                  
  ------------------------------------------------------------------------- ---------------------------- ----------- ------------------- -------------- ----------- ------------------------ ----------------------------------------------- ------------------ ----------------------------------
  **HSV-1 Detection in Clinically Diagnosed GUD (n** = **8**)                                                                                                                                                                                                   

  Chu et al (2006) \[[@CIT0073]\]                                           NA                           Thailand    Hospital            CS             Conv        PCR                      Patients with genital ulcers                    26                 0.0

  Chua and Cheong (1995) \[[@CIT0080]\]                                     1993                         Singapore   Outpatient clinic   CS             Conv        CF                       Male patients with primary genital ulcers       121                8.3

  Chua and Cheong (1995) \[[@CIT0080]\]                                     1993                         Singapore   Outpatient clinic   CS             Conv        CF                       Female patients with primary genital ulcers     54                 27.8

  Chua and Cheong (1995) \[[@CIT0080]\]                                     1993                         Singapore   Outpatient clinic   CS             Conv        CF                       Male patients with recurrent genital ulcer      181                1.6

  Chua and Cheong (1995) \[[@CIT0080]\]                                     1993                         Singapore   Outpatient clinic   CS             Conv        CF                       Female patients with recurrent genital ulcers   24                 0.0

  Hooi et al (2002) \[[@CIT0081]\]                                          1990--1999                   Malaysia    Hospital            CS             Conv        IF                       Patients attending a university hospital        102                28.4

  Hooi et al (2002) \[[@CIT0081]\]                                          1990--1999                   Malaysia    Outpatient clinic   CS             Conv        IF                       Patients attending an STD clinic                204                3.4

  Thirumoorthy et al (1986) \[[@CIT0082]\]                                  1984                         Singapore   Outpatient clinic   CS             Conv        IF                       Male patients with penile ulcers                80                 0.0

  **HSV-1 Detection in Clinically Diagnosed Genital Herpes (n** = **24**)                                                                                                                                                                                       

  Cheong et al (1990) \[[@CIT0083]\]                                        1986--1987                   Singapore   Hospital            CS             Conv        IF                       First genital herpes episode                    62                 33.9

  Chiam et al (2010) \[[@CIT0084]\]                                         1982--2008                   Malaysia    Hospital            CS             Conv        DFA                      Malaysian patients                              49                 61.2

  Chiam et al (2010) \[[@CIT0084]\]                                         1982--2008                   Malaysia    Hospital            CS             Conv        DFA                      Indian patients                                 36                 50.0

  Chiam et al (2010) \[[@CIT0084]\]                                         1982--2008                   Malaysia    Hospital            CS             Conv        DFA                      Chinese patients                                30                 6.7

  Chio et al (2015) \[[@CIT0046]\]                                          2014                         Singapore   Outpatient clinic   CS             Conv        PCR                      Patients with genital herpes                    193                13.9

  Chua and Cheong (1995) \[[@CIT0080]\]                                     1993                         Singapore   Outpatient clinic   CS             Conv        CF                       Male patients with primary genital herpes       98                 10.2

  Chua and Cheong (1995) \[[@CIT0080]\]                                     1993                         Singapore   Outpatient clinic   CS             Conv        CF                       Female patients with primary genital herpes     52                 28.9

  Chua and Cheong (1995) \[[@CIT0080]\]                                     1993                         Singapore   Outpatient clinic   CS             Conv        CF                       Male patients with recurrent genital herpes     116                2.5

  Chua and Cheong (1995) \[[@CIT0080]\]                                     1993                         Singapore   Outpatient clinic   CS             Conv        CF                       Female patients with recurrent genital herpes   19                 0.0

  Doraisingham et al (1987) \[[@CIT0085]\]                                  1984--1986                   Singapore   Hospital            CS             Conv        IF                       Genital lesions positive for HSV                215                21.4

  Doraisingham et al (1987) \[[@CIT0085]\]                                  1984--1986                   Singapore   Hospital            CS             Conv        IF                       Genital HSV isolates                            49                 32.7

  Hooi et al (2002) \[[@CIT0081]\]                                          1990--1999                   Malaysia    Hospital            CS             Conv        IF                       Patients attending a university hospital        55                 52.7

  Hooi et al (2002) \[[@CIT0081]\]                                          1990--1999                   Malaysia    Outpatient clinic   CS             Conv        IF                       Patients attending an STD clinic                165                4.2

  Ishiguro et al (1982) \[[@CIT0086]\]                                      1975--1978                   Japan       Outpatient clinic   CS             Conv        Nab                      Patients with genital herpes                    13                 53.8

  Jacob et al (1989) \[[@CIT0087]\]                                         1983--1986                   India       Outpatient clinic   CS             Conv        IF                       Patient with primary genital herpes             10                 10.0

  Jacob et al (1989) \[[@CIT0087]\]                                         1983--1986                   India       Outpatient clinic   CS             Conv        IF                       Patient with recurrent genital herpes           42                 0.0

  Kao et al (1991) \[[@CIT0088]\]                                           1981--1990                   Taiwan      Hospital            CS             Conv        IF                       Genital HSV isolates in men                     53                 0.0

  Kao et al (1991) \[[@CIT0088]\]                                           1981--1990                   Taiwan      Hospital            CS             Conv        IF                       Genital HSV isolates in women                   96^a^              9.4

  Kawana et al (1982) \[[@CIT0047]\]                                        NA                           Japan       Outpatient clinic   CS             Conv        Nab                      Patients with primary genital herpes            50                 62.0

  Kawana et al (1982) \[[@CIT0047]\]                                        NA                           Japan       Outpatient clinic   CS             Conv        Nab                      Patients with recurrent genital herpes          49                 10.2

  Puthavathana et al (1998) \[[@CIT0089]\]                                  1994--1996                   Thailand    Hospital            CS             Conv        IF                       Women with genital herpes                       75                 18.7

  Sen et al (2008) \[[@CIT0090]\]                                           1996--2006                   Singapore   Outpatient clinic   CS             Conv        PCR                      Patients with genital herpes                    13                 53.8

  Theng and Chan (2004) \[[@CIT0091]\]                                      2001                         Singapore   Outpatient clinic   CS             Conv        IF                       First genital herpes episode                    114                19.3

  Theng and Chan (2004) \[[@CIT0091]\]                                      2001                         Singapore   Outpatient clinic   CS             Conv        IF                       Recurrent genital herpes episode                127                4.7
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CF, complement fixation; Conv, convenience; CS, cross-sectional; DFA, direct fluorescent assay; GUD, genital ulcer disease; HSV-1, herpes simplex virus type 1; IF, immunofluorescence; NA, not available; Nab, neutralization antibody test; PCR, polymerase chain reaction; STD, sexually transmitted disease.

^a^This population included a mix of patients with clinically diagnosed genital herpes and patients suspected of a viral infection from whom cervical swab samples were collected (n = 47).

###### 

Pooled Proportions in Asia of Herpes Simplex Virus Type 1 Viral Detection in Clinically Diagnosed Genital Ulcer Disease or Genital Herpes

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Population Type                                     Measures,\   Samples,\   Proportion of HSV-1 Detection, %   Pooled Proportion of HSV-1 Detection Mean (95% CI), %   Heterogeneity Measure^a^                                        
                                                      Total\       Total\                                                                                                                                                                 
                                                      No.          No.                                                                                                                                                                    
  --------------------------------------------------- ------------ ----------- ---------------------------------- ------------------------------------------------------- -------------------------- ---------------- ------------------- -----------
  Patients with clinically diagnosed GUD              8            792         0.0--28.4                          2.5                                                     5.6 (.8--13.6)             91.1 (\<.001)    92.3 (87.2--95.4)   0.0--43.7

  Patients with clinically diagnosed genital herpes   24           1781        0.0--62.0                          16.3                                                    18.8 (12.0--26.7)          330.4 (\<.001)   93.0 (90.8--94.7)   0.0--62.9
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CI, confidence interval; GUD, genital ulcer disease; HSV-1, herpes simplex virus type 1.

^a^The Cochran *Q* statistic is a measure assessing the existence of heterogeneity in effect size; *I*^2^, a measure that assesses the magnitude of between-study variation due to actual differences in effect size across studies rather than chance; and prediction interval, a measure that estimates the distribution (95% interval) of true effect sizes around the estimated mean.

The proportion of HSV-1 detection in GUD ranged between 0.0% and 28.4%, with a median of 2.5%. The pooled mean proportion was 5.6% (n = 8; 95% CI, 0.8%--13.6%). The proportion of HSV-1 detection in genital herpes ranged between 0.0% and 62.0%, with a median of 16.3%. The pooled mean proportion was 18.8% (n = 24; 95% CI, 12.0%--26.7%). HSV-1 was more frequently detected in first-episode genital herpes than in recurrent genital herpes ([Table 4](#T4){ref-type="table"}).

Quality Assessment {#s18}
------------------

Outcomes of the quality assessment are shown in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}. Overall, seroprevalence studies were of reasonable quality. Of all studies, 70.4% were of high precision, 7.4% had low ROB in the sampling method domain, and 38.9% had low ROB in the response rate domain. Only 7.4% of studies had high ROB in both quality domains.

DISCUSSION {#s19}
==========

We presented a comprehensive systematic review and synthesis of HSV-1 epidemiology in Asia. Fifty percent of children and 75% of adults were infected. Seroprevalence increased with age, with most infections acquired in childhood. No evidence was found for a temporal trend; seroprevalence appeared stable for 3 decades. Nonetheless, seroprevalence was 60% higher in those aged ≥40 than in those aged \<20 years, possibly reflecting a higher exposure risk in earlier times, and an earlier transition toward lower seroprevalence.

As many as 50% of youth reach sexual debut with no protective antibodies against HSV-1, and thus potentially at risk of sexual acquisition. Remarkably, based on virological diagnosis studies, there was a substantial role for HSV-1 in genital herpes and GUD: 19% of genital herpes cases were due to HSV-1 (as opposed to HSV-2), and 6% of GUD cases. These findings suggest an apparently ongoing HSV-1 epidemiological transition, as in Western countries \[[@CIT0005], [@CIT0007], [@CIT0026]\], possibly mediated by Asia's rapid socioeconomic modernization.

The seroprevalence of HSV-1 varied somewhat by country income but was highest in upper-middle-income countries (including China). The weaker socioeconomic association may relate to recent modernization, say for China, and to unexplained low seroprevalence in populations on the Indian subcontinent \[[@CIT0092]\]; seroprevalence in adults was 93% in China but only 67% in India.

Strikingly, there were no differences in seroprevalence by sex, population type, assay type, sampling method, or sample size. Age was the only major predictor of seroprevalence. This speaks for how HSV-1 is a general-population infection that permeates all strata of society. This also demonstrates the ease of sampling a representative sample to measure seroprevalence, provided that the sample age distribution is representative of the underlying population age distribution.

Although seroprevalence was much higher in older than in younger cohorts, there was no evidence for a recent temporal decline in seroprevalence. This finding may be explained by an earlier transition toward lower seroprevalence, or (speculatively) by a demographic effect. HSV-1 seroincidence could be declining, but with rapidly declining fertility and increasing life expectancy rates, the overall seroprevalence could remain stable, masking the decline in seroincidence. Findings from community-based Japanese study (performed over 2 decades) seem to support such a conjecture; seroprevalence in persons aged 20--49 years declined by nearly 10% every decade \[[@CIT0059]\].

Our study has limitations. Data availability varied by country and no data were identified for 13 mostly lower-income countries and territories (Bhutan, Brunei, Cambodia, Hong Kong, Laos, Macau, Mongolia, Myanmar, Nepal, Papua New Guinea, North Korea, Tibet, and Timor-Leste). Seroprevalence showed high heterogeneity, but examined predictors explained only 34% of the variation. Different diagnostic assays were used across studies, but assays may vary by sensitivity and specificity (eg, ELISA vs Western blot) \[[@CIT0043], [@CIT0044]\], as well as in the differential effect of HSV-2 antibodies---particularly for the classic "relative reactivity" methods \[[@CIT0093]\]. However, no evidence was found for differences in seroprevalence by assay type ([Table 3](#T3){ref-type="table"}).

Similarly, various diagnostic assays were used for viral detection (immunofluorescence, direct fluorescent assay, neutralization antibody test, and nucleic acid amplification test), but these may differ in HSV-1 detection \[[@CIT0096]\]. HSV-1 detection in GUD and genital herpes varied across studies, possibly reflecting variation in the underlying epidemiology. For example, a Malaysian study found \>50% HSV-1 detection rates in genital herpes in a university hospital, but \<5% in a sexually transmitted disease clinic \[[@CIT0081]\], probably reflecting differences in the populations attending these facilities (general vs sexual high-risk population).

In conclusion, HSV-1 seroprevalence remains high in Asia, with 50% of children and 75% of adults testing seropositive. However, there seems to be an epidemiological transition, with lower seroprevalence in younger cohorts. Close to 50% of youth reach sexual debut uninfected and potentially at risk of sexual acquisition. HSV-1 is possibly playing an influential role as an STI, explaining a fraction of GUD and genital herpes diagnoses. These findings demonstrate the importance of seroprevalence monitoring and GUD/genital herpes etiological surveillance, as well as expansion of HSV-1 epidemiology research in different age groups and countries; for half of countries, no data were available. These findings also highlight the need to accelerate HSV-1 vaccine development to control transmission and prevent associated clinical and psychosocial disease burden.

Supplementary Data {#s20}
==================

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.
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